Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials

BACKGROUND: Pirfenidone is an oral antifibrotic agent that has been shown to reduce the decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). We performed an integrated analysis of safety data from five clinical trials evaluating pirfenidone in patients with IPF. METHODS: Al...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMJ Open Respir Res
Päätekijät: Lancaster, Lisa, Albera, Carlo, Bradford, Williamson Z, Costabel, Ulrich, du Bois, Roland M, Fagan, Elizabeth A, Fishman, Robert S, Glaspole, Ian, Glassberg, Marilyn K, King, Talmadge E, Lederer, David J, Lin, Zhengning, Nathan, Steven D, Pereira, Carlos A, Swigris, Jeffrey J, Valeyre, Dominique, Noble, Paul W
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2016
Aiheet:
Interstitial Lung Disease
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4716177/
https://ncbi.nlm.nih.gov/pubmed/26835133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjresp-2015-000105
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia